Cargando…

Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine

The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regen...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurent, Alexis, Abdel-Sayed, Philippe, Hirt-Burri, Nathalie, Scaletta, Corinne, Michetti, Murielle, de Buys Roessingh, Anthony, Raffoul, Wassim, Applegate, Lee Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533713/
https://www.ncbi.nlm.nih.gov/pubmed/34685505
http://dx.doi.org/10.3390/cells10102526
_version_ 1784587379854540800
author Laurent, Alexis
Abdel-Sayed, Philippe
Hirt-Burri, Nathalie
Scaletta, Corinne
Michetti, Murielle
de Buys Roessingh, Anthony
Raffoul, Wassim
Applegate, Lee Ann
author_facet Laurent, Alexis
Abdel-Sayed, Philippe
Hirt-Burri, Nathalie
Scaletta, Corinne
Michetti, Murielle
de Buys Roessingh, Anthony
Raffoul, Wassim
Applegate, Lee Ann
author_sort Laurent, Alexis
collection PubMed
description The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration.
format Online
Article
Text
id pubmed-8533713
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85337132021-10-23 Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine Laurent, Alexis Abdel-Sayed, Philippe Hirt-Burri, Nathalie Scaletta, Corinne Michetti, Murielle de Buys Roessingh, Anthony Raffoul, Wassim Applegate, Lee Ann Cells Review The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration. MDPI 2021-09-24 /pmc/articles/PMC8533713/ /pubmed/34685505 http://dx.doi.org/10.3390/cells10102526 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Laurent, Alexis
Abdel-Sayed, Philippe
Hirt-Burri, Nathalie
Scaletta, Corinne
Michetti, Murielle
de Buys Roessingh, Anthony
Raffoul, Wassim
Applegate, Lee Ann
Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
title Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
title_full Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
title_fullStr Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
title_full_unstemmed Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
title_short Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine
title_sort evolution of diploid progenitor lung cell applications: from optimized biotechnological substrates to potential active pharmaceutical ingredients in respiratory tract regenerative medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533713/
https://www.ncbi.nlm.nih.gov/pubmed/34685505
http://dx.doi.org/10.3390/cells10102526
work_keys_str_mv AT laurentalexis evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT abdelsayedphilippe evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT hirtburrinathalie evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT scalettacorinne evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT michettimurielle evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT debuysroessinghanthony evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT raffoulwassim evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine
AT applegateleeann evolutionofdiploidprogenitorlungcellapplicationsfromoptimizedbiotechnologicalsubstratestopotentialactivepharmaceuticalingredientsinrespiratorytractregenerativemedicine